End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
59 CNY | -4.08% | +1.37% | -31.41% |
Apr. 29 | MGI Tech Showcases Life Science Excellence At ESCMID Global 2024 with Latest DNBSEQ-E25 Sequencer | CI |
Apr. 28 | MGI Tech Co. Ltd. Opens Customer Experience Center in Brazil | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-31.41% | 3.51B | - | ||
+8.88% | 221B | B | ||
+8.68% | 186B | B- | ||
+14.25% | 137B | B- | ||
+28.18% | 109B | A- | ||
-0.15% | 63.09B | A- | ||
+14.65% | 52.68B | B+ | ||
+4.48% | 50.86B | B+ | ||
+4.39% | 42.53B | A | ||
+7.00% | 37.76B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688114 Stock
- Ratings MGI Tech Co., Ltd.